TUBB3和MAPT预测非小细胞肺癌对紫杉类药物敏感性的研究  

Predictive value of TUBB3 and MAPT expression in patients with non-small cell lung cancer receiving chemotherapy with taxanes

作　　者：戴宏宇[1] 李苏宜[2] 马国栋[1] 万明月[1] 喻存俊[1] 陈文萍[1] 

机构地区：[1]南京南京市胸科医院呼吸科,210029 [2]安徽省肿瘤医院肿瘤内科,230031

出　　处：《临床肿瘤学杂志》2015年第4期322-326,共5页Chinese Clinical Oncology

基　　金：南京市卫生局医学科技发展项目(YKK09146)

摘　　要：目的探讨Ⅲ型β-微管蛋白(TUBB3)和微管相关蛋白tau(MAPT)在非小细胞肺癌(NSCLC)组织中的表达水平及其对紫杉类化疗药物敏感性的预测价值。方法收集55例未经化疗的不能手术的转移性或复发晚期NSCLC患者的肿瘤组织标本,一线治疗均采用铂类联合紫杉类双药化疗方案,2个周期后评估疗效,将完全缓解和部分缓解的患者归为敏感组,疾病稳定的患者归为次敏感组,疾病进展的患者归为耐药组。采用逆转录-聚合酶链反应检测3组TUBB3和MAPT的mRNA水平,分析NSCLC组织中TUBB3和MAPT mRNA的相关性,采用免疫组织化学法检测3组TUBB3和MAPT的蛋白表达情况。结果在55例NSCLC组织中,TUBB3和MAPT mRNA在3组均有不同程度的表达,且两者蛋白均定位在细胞质内。敏感组、次敏感组及耐药组的TUBB3 mRNA水平分别为0.12±0.13、0.17±0.24和0.51±0.19,MAPT mRNA水平分别为0.09±0.05、0.14±0.09和0.46±0.21,TUBB3阳性表达率分别为22.22%(4/18)、20.00%(5/20)和70.59%(12/17),MAPT阳性表达率分别为16.67%(3/18)、25.00%(4/20)和52.94%(9/17);耐药组的TUBB3和MAPT mRNA水平及阳性率均高于其余两组(P<0.05),且敏感组和次敏感组的以上差异均无统计学意义(P>0.05)。TUBB3和MAPT的mRNA水平呈正相关(r=0.219,P=0.047)。结论 TUBB3和MAPT的mRNA和蛋白表达与紫杉类药物的敏感性有关,高表达者提示对紫杉类药物耐药,联合检测TUBB3和MAPT可能对紫杉类药物化疗敏感性具有较好的预测价值。Objective To explore the expressions of class Ⅲ β-tubulin（ TUBB3） and microtubule associated protein-tau（MAPT） in tumor tissue of patients with non-small cell lung cancer（NSCLC）,and to evaluate the value of TUBB3 and MAPT in predicting the chemosensitivity of taxanes. Methods The tumor tissue specimens from 55 patients with chemo-naive and unoperable metastatic or recurrent NSCLC were collected. All patients received platinum-taxanes chemotherapy as the first-line therapy. According to the efficacy assessed after two cycles,55 patients were divided into 3 groups. Patients with complete remission or partial remission were classed as sensitive group,and patients with stable disease were less sensitive group,and patients with progressive disease were resistance group. Reverse transcription polymerase chain reaction was used to measure the mRNA levels of TUBB3 and MAPT,and the correlation between mRNA expression of TUBB3 and MAPT were analyzed. The immunohistochemistry was used to detect the protein expression levels of TUBB3 and MAPT. Results Expression of TUBB3 and MAPT mRNA in 55 cases of NSCLC tissues were obesrved in varying degrees. TUBB3 and MAPT protein were located in cytoplasm. In sensitive group,less sensitive group and resistance group,the levels of TUBB3 mRNA were 0. 12 ± 0. 13,0. 17 ± 0. 24 and 0. 51 ± 0. 19 and the levels of MAPT mRNA were 0. 09 ± 0. 05,0. 14± 0. 09 and 0. 46 ± 0. 21,respectively. The positive expression rates of TUBB3 and MAPT were 22. 22%（4 /18） and 16. 67%（3 /18）in sensitive group,20. 00%（5 /20） and 25. 00%（4 /20） in less sensitive group,and 70. 59%（12 /17） and 52. 94%（9 /17） in resistance group. The mRNA levels and positive expression rates of both TUBB3 and MAPT were higher in resistance group versus other two groups（ P 〈 0. 05）. No significant difference were observed on the above indices between sensitive group and less sensitive group（ P 〉0. 05）. There was a positive correlation between the mRNA expression of TUBB3 and MA

关 键 词：Ⅲ型β-微管蛋白 微管相关蛋白tau 非小细胞肺癌 紫杉类药物 化疗敏感性 

分 类 号：R734.2[医药卫生—肿瘤]